D-0899-2023 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0899-2023 was initiated by Lupin Pharmaceuticals Inc. on Jun 27, 2023 and is designated Class III. Reason for recall: Subpotent Drug: Out-of-Specification test results observed in assay test at 21-month long term stability study. The recall status is terminated (terminated Mar 12, 2024). Affected quantity: 3,096 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 19, 2023
Initiation Date
Jun 27, 2023
Termination Date
Mar 12, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,096 bottles

Product description

Amlodipine Besylate Tablets, USP 10 mg, 1000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 U.S, Manufactured by: Lupin Limited, Aurangabad 431 210 India, NDC 68180-721-03

Reason for recall

Subpotent Drug: Out-of-Specification test results observed in assay test at 21-month long term stability study.

Distribution pattern

Product was distributed directly to three distributors in TN and NJ. Product may have been further distributed throughout the United States.

Code information

Lot #: A102887, Exp. 6/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0899-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0899-2023. Report a data issue: hello@regdatalab.com.